Drug Design, Development and Therapy
2026
Jie Yang, Qiqi Yan, Ting Zhang et al.
Esketamine is increasingly being applied for preventing postpartum depression (PPD). However, clinical protocols for this application are inconsistent, particularly concerning the route of administration. The aim was to determine whether esketamine bolus administration differed from continuous infusion in terms of preventing PPD. A total of 503 subjects without prenatal depression undergoing...
Obstetric Anesthesia Digest
November 18, 2025
Li Ren, Ting Zhang, B Zou et al.
1 citation
( JAMA Network Open . 2025;8(2):e2459331. doi: 10.1001/jamanetworkopen.2024.59331) Postpartum depression (PPD) is a widespread condition affecting about 17.7% of new mothers globally, with an even higher incidence of 21.4% reported in China. Cesarean birth (CB) appears to increase the risk of developing PPD compared to vaginal births. Given the growing recognition of esketamine, a derivative of...
National Science Review
September 5, 2025
Huoqing Luo, Ming Chen, Yingjie Ning et al.
1 citation
-methyl-d-aspartate receptor (NMDAR) blockade is crucial for the rapid antidepressant effects of ketamine, the involvement of other mechanisms remains contentious, particularly regarding the role of serotonin, a key neurotransmitter in the target of traditional antidepressants. Here, we demonstrate that ketamine elevates serotonin levels by inhibiting the serotonin transporter (SERT). A...
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
March 20, 2025
Congli Zhang, Yan Yan, Junjie Ma et al.
1 citation
To investigate the effect of esketamine on postoperative depression in frail elderly patients undergoing thoracoscopic radical resection of lung cancer. A total of 88 frail elderly patients undergoing elective thoracoscopic radical resection of lung cancer were assigned randomly (using a randomization table) and in a double-blind way (blinding applies to both researchers and patients) to an...
Pharmacology, biochemistry, and behavior
March 1, 2025
Yiwei Shen, Wei Ran, Dawei Liu et al.
2 citations
Electroconvulsive therapy (ECT) is recognized as one of the most efficacious interventions for depression. However, it is associated with impairments in learning and memory functions. Ketamine has demonstrated potential in mitigating cognitive deficits. Notably, the metabotropic glutamate system is hypothesized to play a pivotal role in cognitive process regulation. Nevertheless, the...
JAMA Network Open
February 3, 2025
Li Ren, Ting Zhang, Bingyu Zou et al.
13 citations
Esketamine has been found to reduce the incidence of postpartum depression (PPD) in randomized clinical trials. However, current evidence from randomized clinical trials does not reflect esketamine's efficacy in clinical settings. To assess the clinical efficacy of intraoperative esketamine administration for preventing PPD among women who underwent cesarean delivery. This randomized clinical...
Progress in Neuro-psychopharmacology and Biological Psychiatry
December 1, 2023
Li Ren
Conventional antidepressants that target monoaminergic receptors require several weeks to be efficacious. This lag represents a significant problem in the currently available treatments for serious depression. Ketamine, acting as an N-methyl-d-aspartate receptor antagonist, was shown to have rapid antidepressant-like effects, marking a significant advancement in the study of mood disorders....
Brain and Behavior
December 11, 2020
Lei Zou, S. Min, Qibin Chen et al.
We previously confirmed that low‐dose ketamine, as an adjunctive anesthetic for electroconvulsive therapy (ECT) in adult patients with depression, accelerates the effects of ECT and reduces the ECT‐induced learning and memory deficits. This study explored the efficacy and safety of low‐dose ketamine in elderly patients with depression.
Journal of ECT
January 6, 2020
Qibin Chen, Jun Dong, Jie Luo et al.
22 citations
OBJECTIVES It remains controversial whether a subanesthetic dose of ketamine could modulate the antidepressant effect of electroconvulsive therapy (ECT) in patients with major depressive disorder. We investigated the effect of ketamine on accelerating the antidepressant efficacy of ECT. METHODS One hundred twenty-seven patients with major depressive disorder were included in this randomized,...
Psychiatry Research
November 1, 2019
Jun Dong, S. Min, H. Qiu et al.
26 citations
This study aimed to investigate the efficacy and safety of intermittent low-dose ketamine on improving the efficacy of ECT. Patients diagnosed with Major Depressive Disorder (MDD) (n = 134) were randomized into 3 groups: routine ECT group (group E, n = 45); repeated ketamine-assisted ECT group (group RK, n = 43), and intermittent ketamine-assisted ECT group (group IK, n = 46). Patients in group...
Journal of Psychiatric Research
September 1, 2018
Li Ren, Jie Deng, S. Min et al.
48 citations
Electroconvulsive therapy (ECT) is one of the most effective treatments for depressive disorder. Sub-anesthetic dose of ketamine exerts a rapid and robust antidepressive effect. However, it is still unclear whether ketamine usage in ECT is efficacious as an antidepressant. We aimed to conduct a systematic review and meta-analysis on the effects of ketamine in ECT among patients with depressive...